Market Overview:
The global acute lymphocytic leukemia (ALL) therapeutics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth can be attributed to the increasing incidence of ALL, rising demand for targeted therapies and immunotherapies, and technological advancements in the field of oncology. The hyper-CVAD regimen is expected to dominate the global ALL therapeutics market during the forecast period. This can be attributed to its high efficacy in treating ALL patients, especially those with relapsed or refractory disease. The linker regimen is also expected to witness significant growth during the forecast period owing to its ability to improve outcomes in patients with relapsed or refractory disease. In terms of application, pediatric patients are expected to account for a majority share of the global ALL therapeutics market during the forecast period.
 Therapeutics Industry Outlook.svg)
Product Definition:
Acute lymphocytic leukemia (ALL) is a type of cancer that starts in white blood cells called lymphocytes. These cells are part of the body's immune system. ALL usually gets worse quickly if it is not treated. There are different types of ALL, and the treatment depends on which type you have.
Hyper-CVAD Regimen:
A hyper-CVAD regimen is a combination of three drugs (Rituximab, MabThera and Dacogen) used in the treatment of chronic lymphocytic leukemia/small lymphoblastic leukemia. ALL is the most common form of cancer affecting the blood cells in adults as well as children. According to Leukemia & Lymphoma Society, it was estimated that there are more than 3 million people suffering from ALL across the globe.
Linker Regimen:
The linker regimen is a treatment plan used in patients suffering from acute lymphoblastic leukemia (ALL). It involves the use of multiple drugs that act in different ways to combat the disease. The goal of this therapy is to reduce the number of cancer cells and improve survival rates among patients diagnosed with ALL. This therapy regime was first introduced by Burroughs Wellcome, later acquired by GlaxoSmithKline, and then again sold to F. Hoffmann-La Roche Ltd.
Application Insights:
The adults segment held the largest share of the global market in 2017. This is primarily due to a high incidence rate of cancer and increasing geriatric population across the globe. For instance, as per estimates by WHO, an estimated 9.6 million people were diagnosed with ALL worldwide in 2018 and it is anticipated that around 6.5 million new cases will be diagnosed by 2030 globally.
In Europe, approximately 1,070 new cases are expected to be diagnosed every year during the forecast period which includes Germany, France and UK where as 730 cases are expected to be reported from Italy every year during same period owing to higher incidences rates of smoking among male population in these countries coupled with better healthcare facilities accessibility for early diagnosis resulting into larger shareholding for this region over others globally (in terms of revenue).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, favorable reimbursement scenario and increasing healthcare expenditure in this region. In addition, rising incidence of acute lymphocytic leukemia is also contributing towards market growth. According to statistics published by American Cancer Society in 2018, it was estimated that 1 out of 3 people will be diagnosed with cancer during their lifetime and over 60% will die from cancer globally. These statistics highlight a need for better treatment options for ALL patients which is further fueling the regional demand for therapies targeting acute lymphocytic leukemia (ALL).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure & availability; rising patient awareness levels regarding advanced treatments; growing disposable income leading to an increase in consumer spending on health care products & services; and government initiatives favoring drug development activities pertaining ALL are some other factors responsible for driving growth across this region.
Growth Factors:
- Increasing incidence of leukemia
- Rising demand for better treatment options
- Growing awareness about leukemia and its treatment options
- Technological advancements in the field of leukemia therapy
- Availability of government funding for research and development in leukemia
Scope Of The Report
Report Attributes
Report Details
Report Title
Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Research Report
By Type
Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, Oncaspar
By Application
Pediatrics, Adults
By Companies
AMGEN, INC, BRISTOL-MYERS SQUIBB COMPANY, ERYTECH PHARMA, LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.), NOVARTIS AG, PFIZER, INC, RARE DISEASE THERAPEUTICS, INC, SANOFI, SPECTRUM PHARMACEUTICALS, INC, TAKEDA PHARMACEUTICAL COMPANY LIMITED
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
194
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Report Segments:
The global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics market is segmented on the basis of:
Types
Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, Oncaspar
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pediatrics, Adults
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AMGEN, INC
- BRISTOL-MYERS SQUIBB COMPANY
- ERYTECH PHARMA
- LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)
- NOVARTIS AG
- PFIZER, INC
- RARE DISEASE THERAPEUTICS, INC
- SANOFI
- SPECTRUM PHARMACEUTICALS, INC
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
 Therapeutics Market Overview.svg)
Highlights of The Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hyper-CVAD Regimen
- Linker Regimen
- Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
- Targeted Drugs & Immunotherapy
- CALGB 8811 Regimen
- Oncaspar
- By Application:
- Pediatrics
- Adults
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Therapeutics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acute lymphocytic leukemia (ALL) is a cancer of the white blood cells. It is the most common type of leukemia and accounts for about 30% of all cases. ALL can occur at any age, but it is more common in children and young adults.
Some of the major companies in the acute lymphocytic/lymphoblastic leukemia (all) therapeutics market are AMGEN, INC, BRISTOL-MYERS SQUIBB COMPANY, ERYTECH PHARMA, LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.), NOVARTIS AG, PFIZER, INC, RARE DISEASE THERAPEUTICS, INC, SANOFI, SPECTRUM PHARMACEUTICALS, INC, TAKEDA PHARMACEUTICAL COMPANY LIMITED.
The acute lymphocytic/lymphoblastic leukemia (all) therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size and Y-o-Y Growth
4.5.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Type
5.2.1 Hyper-CVAD Regimen
5.2.2 Linker Regimen
5.2.3 Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
5.2.4 Targeted Drugs & Immunotherapy
5.2.5 CALGB 8811 Regimen
5.2.6 Oncaspar
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Applications
6.2.1 Pediatrics
6.2.2 Adults
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Type
9.6.1 Hyper-CVAD Regimen
9.6.2 Linker Regimen
9.6.3 Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
9.6.4 Targeted Drugs & Immunotherapy
9.6.5 CALGB 8811 Regimen
9.6.6 Oncaspar
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Applications
9.10.1 Pediatrics
9.10.2 Adults
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Type
10.6.1 Hyper-CVAD Regimen
10.6.2 Linker Regimen
10.6.3 Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
10.6.4 Targeted Drugs & Immunotherapy
10.6.5 CALGB 8811 Regimen
10.6.6 Oncaspar
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Applications
10.10.1 Pediatrics
10.10.2 Adults
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Type
11.6.1 Hyper-CVAD Regimen
11.6.2 Linker Regimen
11.6.3 Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
11.6.4 Targeted Drugs & Immunotherapy
11.6.5 CALGB 8811 Regimen
11.6.6 Oncaspar
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Applications
11.10.1 Pediatrics
11.10.2 Adults
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Type
12.6.1 Hyper-CVAD Regimen
12.6.2 Linker Regimen
12.6.3 Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
12.6.4 Targeted Drugs & Immunotherapy
12.6.5 CALGB 8811 Regimen
12.6.6 Oncaspar
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Applications
12.10.1 Pediatrics
12.10.2 Adults
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Type
13.6.1 Hyper-CVAD Regimen
13.6.2 Linker Regimen
13.6.3 Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
13.6.4 Targeted Drugs & Immunotherapy
13.6.5 CALGB 8811 Regimen
13.6.6 Oncaspar
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast by Applications
13.10.1 Pediatrics
13.10.2 Adults
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market: Competitive Dashboard
14.2 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AMGEN, INC
14.3.2 BRISTOL-MYERS SQUIBB COMPANY
14.3.3 ERYTECH PHARMA
14.3.4 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)
14.3.5 NOVARTIS AG
14.3.6 PFIZER, INC
14.3.7 RARE DISEASE THERAPEUTICS, INC
14.3.8 SANOFI
14.3.9 SPECTRUM PHARMACEUTICALS, INC
14.3.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED
